-Secures exclusivity until 2039… Demonstrating the competitiveness of its proprietary technology
-A GFRA1 receptor agonist, positioned as a First-in-Class topical novel drug candidate
-Phase 1 IND application submitted, accelerating full-scale clinical development
January 2026
JW Pharmaceutical announced on the 19th the successful registration of a U.S. patent for 'JW0061,' a novel hair loss treatment candidate targeting the GFRA1 receptor.
The newly registered patent is a substance patent covering the novel heterocyclic derivatives of JW0061, along with their salts and isomers. It protects the technology utilized for the treatment and prevention of various hair loss conditions, including androgenetic alopecia and alopecia areata. With the patent valid until May 2039, JW Pharmaceutical has secured long-term exclusive rights in the U.S. market.
Including this U.S. patent, JW Pharmaceutical has now completed the registration of substance patents for JW0061 in a total of nine countries—including South Korea, Japan, China, Australia, and Brazil—with patent examinations currently underway in regions such as Europe and Canada.
Developed as a topical formulation applied directly to the scalp, JW0061 is a First-in-Class drug candidate operating as a GFRA1 agonist. The compound binds directly to the GFRA1 receptor expressed on hair stem cells, activating downstream signaling pathways to promote hair follicle neogenesis and accelerate hair growth.
A key characteristic of JW0061 is its design, which is based on a mechanism that physiologically activates the body's innate hair growth pathways. This represents a novel mechanism of action that differentiates it from conventional treatments relying on androgen suppression or vasodilation, making it an innovative therapeutic option applicable to both male and female patients.
JW Pharmaceutical has consistently presented preclinical results for JW0061 at major international conferences, including the Society for Investigative Dermatology (SID). In studies utilizing human skin organoids and animal models of androgenetic alopecia, the company confirmed the candidate's superiority over existing standard treatments in terms of hair growth rate and follicle generation capacity. Notably, in the human skin organoid assay, JW0061 demonstrated up to a 7.2-fold increase in hair follicle generation compared to standard therapies. Furthermore, animal models showed up to a 39% improvement in efficacy, firmly establishing its competitive edge as a breakthrough drug candidate.
Building upon these strong preclinical achievements, JW Pharmaceutical recently submitted an Investigational New Drug (IND) application for Phase 1 clinical trials of JW0061 to the Ministry of Food and Drug Safety (MFDS).
“JW0061 is a next-generation novel drug candidate for hair loss targeting the GFRA1 receptor. This U.S. patent registration is highly significant as it represents official recognition of our proprietary technology's competitiveness in the world's largest market,” a JW Pharmaceutical official stated. “We will seamlessly advance our clinical development to establish JW0061 as a global innovative hair loss treatment.”
Meanwhile, JW0061 was previously selected as a supported project by the Korea Drug Development Fund (KDDF) to conduct its non-clinical research phase.